Albireo Pharma, Inc (ALBO)

Etorro trading 970x250
Albireo Pharma, Inc (ALBO) Logo

About Albireo Pharma, Inc

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts. Address: 10 Post Office Square, Boston, MA, United States, 02109

Albireo Pharma, Inc News and around…

Latest news about Albireo Pharma, Inc (ALBO) common stock and company :

Albireo to Showcase New Data at AASLD The Liver Meeting® 2021
15 Oct, 2021 Yahoo! Finance

– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases – – Phase 3 Bylvay™ (odevixibat) data presentations on long-term treatment benefits show evidence of improved liver health and function across PFIC types – – Data presentations on A2342, the first oral systemic sodium-taurocholate co-transporting peptide (NTCP) inhibitor for development in viral and cholestatic liver diseases – – Company to host post-AASLD call on November 16, 2021 at 10 a.m. EST – BOS

Japanese biotech pays Albireo $135M for local liver disease drug rights
12 Oct, 2021 Yahoo! Finance

Japanese biotech Jadeite Medicines is paying Boston-based Albireo Pharma Inc. up to $135 million for Japanese rights to Bylvay, the company's recently approved drug for rare liver diseases.

Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan
12 Oct, 2021 Yahoo! Finance

– Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia – – Albireo to receive upfront payment of $15M and up to $120M in milestones and double-digit royalties – – Bylvay approved in U.S., EU and UK with global prescriptions already generated – BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, entered into an e

The past year for Albireo Pharma (NASDAQ:ALBO) investors has not been profitable
06 Oct, 2021 Yahoo! Finance

It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

Albireo Recognizes PFIC Awareness Day 2021
05 Oct, 2021 Yahoo! Finance

BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis (PFIC). Established in 2019, PFIC Awareness Day aims to highlight the impact of this disease on patients and families, and to call fo

Albireo Announces Bylvay® (odevixibat) Now Available in Germany
15 Sep, 2021 FinancialContent
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08 Sep, 2021 FinancialContent
Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)
08 Sep, 2021 FinancialContent
Albireo Pharma Sells Bylvay-Associated PRV For $105M
07 Sep, 2021 FinancialContent

Albireo Pharma Inc(NASDAQ: ALBO) hasagreed to sellits Priority Review Voucher (PRV) for $105 million. The ...

Albireo Sells Priority Review Voucher (PRV) for $105 Million
07 Sep, 2021 FinancialContent
Albireo to Present at Upcoming Investor Conferences
02 Sep, 2021 FinancialContent
Noteworthy Tuesday Option Activity: CHS, JOE, ALBO
31 Aug, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Chico's FAS Inc (CHS), where a total volume of 11,898 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 71.5% of CHS's average daily trading volume over the past month, of 1.7 million shares..

Looking into Albireo Pharma's Return on Capital Employed
27 Aug, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Albireo Pharma (NASDAQ:ALBO) posted sales of $2.43 million. Earnings were ...

Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region
18 Aug, 2021 Yahoo! Finance

– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC – – PFIC is a life-threatening liver disease and the number one cause of pediatric liver transplants in Saudi Arabia – – King Faisal Research Center was one of the top enrolling sites in the global Phase 3 PEDFIC study – BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, completed an ex-U.S. commercial dis

Albireo Pharma, inc (ALBO) Q2 2021 Earnings Call Transcript
07 Aug, 2021 FinancialContent

ALBO earnings call for the period ending June 30, 2021.

ALBIREO PHARMA (ALBO) Reports Q2 Loss, Misses Revenue Estimates
05 Aug, 2021 Yahoo! Finance

ALBIREO PHARMA (ALBO) delivered earnings and revenue surprises of 1.04% and -6.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Albireo Reports Q2 Financial Results and Business Update
05 Aug, 2021 FinancialContent
Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference
03 Aug, 2021 FinancialContent
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
02 Aug, 2021 FinancialContent

The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly ...

Albireo to Report Second Quarter 2021 Financial Results on August 5
29 Jul, 2021 FinancialContent

— Conference call and webcast to be held at 10:00 a.m. ET — 

Fintech Spotlight: Mexico-Based Insurtech Guros Bags $5.8M At $30M Valuation
28 Jul, 2021 FinancialContent

Guros, a fintech in Mexico that’s transforming theinsurance experience, formally announced the closure of a $5.8 million ...

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs, And More
25 Jul, 2021 FinancialContent

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefited from the optimism that was set in motion by the solid start to the pharma reporting season.

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
25 Jul, 2021 FinancialContent

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism ...

Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug
21 Jul, 2021 Yahoo! Finance

Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.

Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
21 Jul, 2021 FinancialContent

Just aday after European approval,Albireo Pharma Inc(NASDAQ: ALBO)has received FDA approvalfor Bylvay ...

MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
20 Jul, 2021 FinancialContent
Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
20 Jul, 2021 FinancialContent
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease
19 Jul, 2021 FinancialContent

TheEuropean Commission (EC) has approvedAlbireo Pharma Inc's(NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes ...

Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)
19 Jul, 2021 FinancialContent

Albireo Pharma, Inc (ALBO) is a NASDAQ Common Stock listed in , ,

970x250